查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1960022

生物皮膚替代品市場－全球產業規模、佔有率、趨勢、機會、預測：按類型、應用、最終用戶、地區和競爭對手分類，2021-2031年

Biological Skin Substitutes Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Application, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球生物皮膚病替代療法市場預計將從 2025 年的 3.5821 億美元成長到 2031 年的 5.8797 億美元，複合年成長率為 8.61%。

這些生物工程產品由人類、動物或合成材料製成，旨在修復嚴重傷口並實現有效傷口縫合。這個市場的主要成長要素是慢性潰瘍和燒燙傷病例的增加，以及全球人口老化，老年人更容易患上全身性疾病和出現傷口癒合延遲的情況。根據國際糖尿病聯盟（IDF）預測，到2025年，全球將有約5.89億成年人患有糖尿病，因此，利用生物干預手段治療糖尿病足潰瘍和預防截肢已成為亟待解決的問題。

市場概覽
預測期 2027-2031
市場規模：2025年 3.5821億美元
市場規模：2031年 5.8797億美元
複合年成長率：2026-2031年 8.61%
成長最快的細分市場 慢性傷口
最大的市場 北美洲

儘管臨床需求強勁，但高成本構成了市場發展的重大障礙。嚴格的報銷政策和不同醫療保險計劃覆蓋範圍的差異，常常限制了患者獲得這些高品質治療的機會。因此，醫療服務提供者在初始治療中往往優先考慮成本較低的替代方案，而這些經濟障礙也限制了生物皮膚替代品的廣泛應用。

市場促進因素

全球慢性傷口和糖尿病足潰瘍的日益普遍是推動全球生物皮膚替代品市場發展的主要動力。隨著人口老化和糖尿病盛行率的上升，人們對能夠促進難癒合潰瘍組織再生、超越傳統敷料療效的先進生物活性療法的需求日益成長。預防感染疾病和截肢等嚴重併發症的需求也反映在主要企業的財務表現中。例如，Organogenesis Holdings Inc.報告稱，其先進創傷護理產品在2025年第三季的淨產品收入達到1.415億美元，年增31%，凸顯了市場對這些解決方案的高度依賴。

同時，嚴重燒傷和急性創傷病例的不斷增加，持續推高了對有效皮膚替代療法的需求，推動了市場擴張。嚴重燒傷和創傷需要即時進行持續覆蓋以恢復皮膚屏障功能，這促使專業機構採用異質骨移植和同種移植。根據美國燒傷協會發布的《2025年燒傷總結報告》，2024年美國共有32,993例燒傷病例，凸顯了燒傷給患者帶來的沉重負擔。 MiMedx集團2025年第三季淨銷售額創歷史新高，達到1.14億美元，年增35%，進一步印證了這項需求。

市場挑戰

開發和應用生物皮膚替代品的高昂成本嚴重阻礙了市場成長。製造商承擔著複雜的生物工程成本，推高了市場價格，迫使醫療機構往往選擇更經濟實惠的傳統創傷護理方法，而不是這些先進的解決方案。限制性的報銷政策進一步加劇了這種經濟摩擦。不穩定的保險覆蓋範圍常常導致醫療機構面臨理賠被拒的財務風險，促使其採取謹慎的籌資策略。

這些經濟障礙直接限制了患者獲得治療的機會，並降低了醫療機構的採用率。不永續的成本成長導致監管干預增加，支付環境也變得不穩定。根據創傷護理照護利害關係人相關人員發布的《2025年報告》，在聯邦政府於2024年對皮膚替代產品支出超過100億美元後，該產業在保險覆蓋範圍方面面臨更大的不確定性。這種快速成長促使支付方收緊報銷標準並推遲政策實施，從而抑制了這些治療方法的廣泛應用，並減緩了整個行業的成長。

市場趨勢

羊膜來源的同種異體移植片應用激增，正在重塑市場格局。這主要得益於臨床醫師日益重視富含生長因子的組織，以加速慢性傷口的癒合。這些胎盤來源的產品因其能夠減輕發炎和減少疤痕組織而備受推崇，是治療複雜糖尿病潰瘍的理想替代方案，優於傳統的敷料。史密斯醫療（Smith & Nephew）2025年第三季財報顯示，其高級傷口生物活性產品部門的收入實現了兩位數成長，充分體現了市場對其胎盤來源和真皮來源皮膚替代物的強勁需求，也印證了這一趨勢的商業性成功。

同時，生物來源合成混合皮膚支架的研發正在加速推進，以克服純組織基質的機械性質限制。這些先進的移植物將生物來源質與合成聚合物增強材料結合，形成耐用的支架，既能支持組織再生，又能承受複雜修復手術中的結構負荷。 TELA Bio公司的一份報告從數量上印證了這項轉變。該公司宣布，其OviTex增強型組織基質產品線在2025年第三季的銷售額年增了22%，凸顯了外科醫生對這些增強型混合技術的日益青睞。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：生物皮膚替代品的全球市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型（源自人類捐贈者組織的產品、源自無細胞動物的產品、生物合成產品）
    • 按應用（慢性傷口、急性傷口）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美生物皮膚替代品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲生物皮膚替代品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區生物皮膚替代品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲生物皮膚替代品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲生物皮膚替代品市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球生物皮膚替代品市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Organogenesis Inc.
  • Integra LifeSciences Corporation
  • Smith & Nephew, plc
  • Tissue Regenix Group
  • MIMEDX Group, Inc.
  • Stryker Corporation
  • Vericel Corporation
  • 3M Company
  • Bio-Tissue, Inc.
  • Stratatech Corporation

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 15618

The Global Biological Skin Substitutes Market is projected to expand from USD 358.21 Million in 2025 to USD 587.97 Million by 2031, reflecting a compound annual growth rate of 8.61%. These bioengineered products, derived from human, animal, or synthetic sources, are designed to repair severe wounds and provide effective closure. The market is primarily driven by the rising burden of chronic ulcers and burn injuries, alongside an aging global population prone to systemic diseases and slow-healing wounds. According to the International Diabetes Federation, approximately 589 million adults were living with diabetes in 2025, creating an urgent need for biological interventions to treat diabetic foot ulcers and prevent amputations.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 358.21 Million
Market Size 2031USD 587.97 Million
CAGR 2026-20318.61%
Fastest Growing SegmentChronic Wounds
Largest MarketNorth America

Despite robust clinical demand, the market faces significant hurdles related to the high costs of development and application. Stringent reimbursement policies and inconsistent insurance coverage across different healthcare systems frequently restrict patient access to these premium therapies. Consequently, healthcare providers often prioritize lower-cost alternatives for initial treatment, thereby limiting the widespread adoption of biological skin substitutes due to these financial barriers.

Market Driver

The increasing global prevalence of chronic wounds and diabetic foot ulcers acts as a major catalyst for the Global Biological Skin Substitutes Market. As the geriatric population grows and diabetes rates rise, the demand for advanced bioactive therapies to stimulate tissue regeneration in hard-to-heal ulcers intensifies, surpassing the capabilities of conventional dressings. This necessity to prevent severe complications like infection and amputation is reflected in the financial performance of key players; for instance, Organogenesis Holdings Inc. reported a 31% year-over-year increase in net product revenue for Advanced Wound Care products, reaching $141.5 million in the third quarter of 2025, highlighting the heavy reliance on these solutions.

Simultaneously, the rising incidence of severe burn injuries and acute trauma cases propels market expansion by creating sustained demand for effective skin replacement modalities. Severe thermal injuries and trauma require immediate, durable coverage to restore barrier function, driving the adoption of xenografts and allografts in specialized units. The American Burn Association's '2025 Annual Burn Injury Summary Report' noted 32,993 burn cases in 2024, illustrating the significant patient burden. This demand is further evidenced by MiMedx Group, Inc., which achieved record net sales of $114 million in the third quarter of 2025, marking a 35% increase compared to the previous year.

Market Challenge

The substantial expense associated with developing and applying biological skin substitutes constitutes a severe impediment to market growth. Manufacturers incur complex bioengineering costs that result in premium market pricing, leading healthcare providers to frequently favor affordable traditional wound care methods over these advanced solutions. This economic friction is further compounded by restrictive reimbursement policies, where inconsistent insurance coverage often leaves facilities bearing the financial risk of denied claims, resulting in hesitant procurement strategies.

These financial barriers directly limit patient access and reduce adoption rates across medical institutions. The unsustainable trajectory of these costs has triggered increased regulatory intervention and a volatile payment environment. According to the Alliance of Wound Care Stakeholders in 2025, the industry faced heightened coverage uncertainties after federal spending for skin substitute products exceeded $10 billion in 2024. This drastic increase has prompted payers to tighten reimbursement criteria and delay policy implementations, effectively curbing the widespread utilization of these therapies and slowing overall sector expansion.

Market Trends

The market is being reshaped by a surge in the adoption of amniotic membrane-derived allografts, as clinicians increasingly prioritize tissues rich in growth factors for stalling chronic wounds. These placental-based products are favored for their ability to reduce inflammation and minimize scar tissue, offering a superior alternative to conventional dressings for managing complex diabetic ulcers. The commercial success of this trend is highlighted by Smith+Nephew's 'Third Quarter 2025 Trading Report', which noted double-digit revenue growth in the Advanced Wound Bioactives segment, reflecting robust demand for its placental and dermal skin substitutes.

Concurrently, the development of hybrid biological-synthetic skin scaffolds is gaining momentum to address the mechanical limitations of pure tissue matrices. These advanced grafts integrate biologic substrates with synthetic polymer reinforcement, creating durable scaffolds that support tissue regeneration while withstanding structural loads in complex repairs. This shift is quantitatively evidenced by TELA Bio, Inc., which reported a 22% year-over-year increase in unit sales for its OviTex Reinforced Tissue Matrix portfolio in the third quarter of 2025, underscoring a growing surgeon preference for these reinforced hybrid technologies.

Key Market Players

  • Organogenesis Inc.
  • Integra LifeSciences Corporation
  • Smith & Nephew, plc
  • Tissue Regenix Group
  • MIMEDX Group, Inc.
  • Stryker Corporation
  • Vericel Corporation
  • 3M Company
  • Bio-Tissue, Inc.
  • Stratatech Corporation

Report Scope

In this report, the Global Biological Skin Substitutes Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Biological Skin Substitutes Market, By Type

  • Human Donor Tissue-Derived Products
  • Acellular Animal Derived Products
  • Biosynthetic Products

Biological Skin Substitutes Market, By Application

  • Chronic Wounds
  • Acute Wounds

Biological Skin Substitutes Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Biological Skin Substitutes Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Biological Skin Substitutes Market.

Available Customizations:

Global Biological Skin Substitutes Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Biological Skin Substitutes Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Human Donor Tissue-Derived Products, Acellular Animal Derived Products, Biosynthetic Products)
    • 5.2.2. By Application (Chronic Wounds, Acute Wounds)
    • 5.2.3. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Biological Skin Substitutes Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Application
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Biological Skin Substitutes Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Biological Skin Substitutes Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Biological Skin Substitutes Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By End User

7. Europe Biological Skin Substitutes Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Application
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Biological Skin Substitutes Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By End User
    • 7.3.2. France Biological Skin Substitutes Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Biological Skin Substitutes Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Biological Skin Substitutes Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Application
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Biological Skin Substitutes Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Application
        • 7.3.5.2.3. By End User

8. Asia Pacific Biological Skin Substitutes Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Application
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Biological Skin Substitutes Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By End User
    • 8.3.2. India Biological Skin Substitutes Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Biological Skin Substitutes Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Biological Skin Substitutes Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Application
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Biological Skin Substitutes Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Application
        • 8.3.5.2.3. By End User

9. Middle East & Africa Biological Skin Substitutes Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Application
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Biological Skin Substitutes Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Biological Skin Substitutes Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Biological Skin Substitutes Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By End User

10. South America Biological Skin Substitutes Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Application
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Biological Skin Substitutes Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Application
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Biological Skin Substitutes Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Application
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Biological Skin Substitutes Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Application
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Biological Skin Substitutes Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Organogenesis Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Integra LifeSciences Corporation
  • 15.3. Smith & Nephew, plc
  • 15.4. Tissue Regenix Group
  • 15.5. MIMEDX Group, Inc.
  • 15.6. Stryker Corporation
  • 15.7. Vericel Corporation
  • 15.8. 3M Company
  • 15.9. Bio-Tissue, Inc.
  • 15.10. Stratatech Corporation

16. Strategic Recommendations

17. About Us & Disclaimer